Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.67 |
| ▸ | BCHE | P06276 | 3/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.52 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212441 | 0.85 | CHRM1 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8343846 | 0.84 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3330915 | 0.83 | SMN1; SMN2 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24724241 | 0.82 | MEN1 (0.56) | HDAC6SMYD3BRD4CHRM1KMT2A | |
| SCHEMBL12123931 | 0.81 | SLC6A4 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29200503 | 0.79 | KHK (0.60) | SMYD3SLC6A4 | |
| SCHEMBL6600119 | 0.79 | SMYD3 (0.56) | MAOBSMYD3ACSS2NAMPT | |
| SCHEMBL3017757 | 0.79 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5365652 | 0.79 | SMYD3 (0.57) | HDAC6SMYD3BRD4CHRM1KMT2A | |
| SCHEMBL30475500 | 0.78 | HPGD (0.61) | SMYD3BRD4HTR4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394831-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394831-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-16 | — | — | US | disclosed |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-16 | — | — | US | disclosed |
| US-8071615-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071615-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2009-02-12 | — | — | US | disclosed |
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2009-02-12 | — | — | US | disclosed |
| US-7446109-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |
| US-7446109-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | HDAC3 2/4885HDAC4 8/4885HDAC1 1/4885 |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | HDAC3 2/4885HDAC4 8/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.